Sichuan Kelun Pharmaceutical Co., Ltd. (SHE:002422)
| Market Cap | 57.13B -5.7% |
| Revenue (ttm) | 18.38B -8.0% |
| Net Income | 1.57B -37.0% |
| EPS | 0.99 -36.9% |
| Shares Out | 1.59B |
| PE Ratio | 36.28 |
| Forward PE | 23.66 |
| Dividend | 0.59 (1.65%) |
| Ex-Dividend Date | May 11, 2026 |
| Volume | 23,207,691 |
| Open | 37.89 |
| Previous Close | 35.62 |
| Day's Range | 34.58 - 37.89 |
| 52-Week Range | 28.14 - 41.72 |
| Beta | -0.09 |
| Analysts | Buy |
| Price Target | 41.29 (+14.95%) |
| Earnings Date | Aug 18, 2026 |
About SHE:002422
Sichuan Kelun Pharmaceutical Co., Ltd. researches, develops, produces, and sells infusion and non-infusion pharmaceutical products in China and internationally. The company operates through Chuanning, Botai, and Other Business segments. The company offers infusion products; oral medication and other dosage form; medical devices, such as infusion sets, sterile dispensing and injection syringes, vein detained needles, nebulizer sets, and vacuum blood collection tubes; over-the-counter products; and APIs to treat cardiovascular, IPF, ED, anti-tumo... [Read more]
Financial Performance
In 2025, SHE:002422's revenue was 18.51 billion, a decrease of -15.13% compared to the previous year's 21.81 billion. Earnings were 1.70 billion, a decrease of -42.03%.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for 002422 stock is "Buy." The 12-month stock price target is ¥41.29, which is an increase of 14.95% from the latest price.
News
Sichuan Kelun Pharmaceutical Quarterly report: Q1 2026
Sichuan Kelun Pharmaceutical has published its Q1 2026 quarterly earnings report on April 28, 2026.
Sichuan Kelun Pharmaceutical Earnings Call Transcript: H2 2025
Revenue grew 6.5% to RMB 2.06 billion in 2025, driven by expanded commercialization and strong R&D pipeline. Gross margin outpaced revenue growth, but net loss increased due to higher sales and R&D expenses. Multiple new approvals, global partnerships, and AI-driven R&D position the company for further growth.
Sichuan Kelun Pharmaceutical Annual report: H2 2025
Sichuan Kelun Pharmaceutical has published its H2 2025 annual report on March 23, 2026.
Sichuan Kelun Pharmaceutical Transcript: 44th Annual J.P. Morgan Healthcare Conference
The company highlighted its leadership in ADC innovation, with four approved products and a robust pipeline targeting oncology and beyond. Strategic partnerships and inclusion in China's NRDL 2025 support commercialization and global expansion.
Crescent, Kelun-Biotech Sign Oncology Deal; Crescent To Raise $185 Mln; Stock Up
(RTTNews) - Crescent Biopharma, Inc. (CBIO), on Thursday announced an exclusive partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. to develop and commercialize oncology therapeutics, i...
Sichuan Kelun Pharmaceutical Quarterly report: Q3 2025
Sichuan Kelun Pharmaceutical has published its Q3 2025 quarterly earnings report on October 31, 2025.
Sichuan Kelun Pharmaceutical Earnings Call Transcript: H1 2025
Reported RMB 950 million revenue in 1H 2025, driven by first-year commercialization and robust R&D partnerships. Lung cancer led sales, with strong clinical progress and a solid cash position supporting future growth.
Sichuan Kelun Pharmaceutical Quarterly report: H1 2025
Sichuan Kelun Pharmaceutical has published its H1 2025 quarterly earnings report on August 17, 2025.